Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Bernardi, Massimo  [Clear All Filters]
Journal Article
Oltolini C, Greco R, Galli L, Clerici D, Lorentino F, Xue E, Stanghellini MTeresa Lup, Giglio F, Uhr L, Ripa M, et al. Infections after allogenic transplant with post-transplant cyclophosphamide: impact of donor HLA-matching. Biol Blood Marrow Transplant. 2020.
Ferreri AJM, Doorduijn JK, Re A, Cabras MGiuseppina, Smith J, Ilariucci F, Luppi M, Calimeri T, Cattaneo C, Khwaja J, et al. MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial. Lancet Haematol. 2021;8(2):e110-e121.
Greco R, Nitti R, Mancini N, Pasciuta R, Lorentino F, Lupo-Stanghellini MTeresa, Barbanti MChiara, Clementi N, Giglio F, Clerici D, et al. Microbiome Markers are Early Predictors of Acute GvHD in Allogeneic Hematopoietic Stem Cell Transplant recipients. Blood. 2020.
Clerici D, Oltolini C, Greco R, Ripa M, Giglio F, Mastaglio S, Lorentino F, Pavesi F, Farina F, Liberatore C, et al. The place in therapy of ceftazidime/avibactam and ceftolozane/tazobactam in hematological patients with febrile neutropenia. Int J Antimicrob Agents. 2021:106335.
Greco R, Lorentino F, Albanese S, Stanghellini MTeresa Lup, Giglio F, Piemontese S, Clerici D, Lazzari L, Marcatti M, Mastaglio S, et al. Post-Transplant Cyclophosphamide and Sirolimus based Graft-versus-Host-Disease Prophylaxis in Allogeneic Stem Cell Transplant. Transplant Cell Ther. 2021.
Porta MGDella, Alessandrino EPaolo, Bacigalupo A, van Lint MTeresa, Malcovati L, Pascutto C, Falda M, Bernardi M, Onida F, Guidi S, et al. Predictive factors for the outcome of allogeneic transplantation in patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System (IPSS-R). Blood. 2014.
Xue E, Lorentino F, Pavesi F, Assanelli A, Peccatori J, Bernardi M, Corti C, Ciceri F, Stanghellini MTeresa Lup. Ruxolitinib for chronic steroid-refractory graft versus host disease: a single center experience. Leuk Res. 2021;109:106642.